Ispire Technology Inc's Stock Price Drops 7.1%

Business by 2FIRSTS.ai

Nov.17.2023

Ispire Technology Inc's Stock Price Drops 7.1%

Ispire Technology Inc (ISPR) shares plummeted 7.1% to $12.76 during trading on Thursday, with approximately 29,991 shares traded.

According to Dispatchtribunal, the stock price of Nasdaq-listed company Ispire Technology Inc (ISPR) fell by 7.1% during Thursday's (November 16th) trading session, reaching a lowest trading price of $12.76.

According to reports, approximately 29,991 shares were traded during the trading period, marking a significant decline of 56% compared to the daily average trading volume of 67,846 shares.

References:

[1] Ispire Technology (NASDAQ:ISPR) Trading Down 7.1%

Also Read:

[1] Ispire Technology Inc. Reports Strong Financial Performance in Q1 2024

#United States #Technology.#Ispire Technologies Inc.

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

Copyright

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

AI Assistance Disclaimer

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

2Firsts Exclusive | AVM President Allison Boughner: The U.S. Vape Market Reshapes Under a Regulatory Storm

Amid intensified regulation and sweeping market shifts, the U.S. vaping industry is undergoing a profound transformation. In an exclusive interview with 2Firsts, AVM President Allison Boughner discusses how enforcement is reshaping brands, distribution, products, compliance, and U.S.-based manufacturing.

Oct.20

Ukraine Military Voices Concern Over Potential Vape and Pouch Ban

Verkhovna Rada is reviewing six bills to regulate new nicotine products such as pouches and vapes. The main bill, No.14110, proposes a total ban on production, import, and sale, while alternative proposals seek regulation instead of prohibition.

Nov.10 by 2FIRSTS.ai

U.S. 25 Attorneys General Urge Shopify to Block Illegal E-Cigarette Sales

California Attorney General Rob Bonta and the City of New York co-led a bipartisan coalition of 25 attorneys general in urging Shopify Inc. to take stronger measures against merchants selling illegal e-cigarettes and other tobacco products through its platform. The letter calls for cooperation between Shopify and U.S. states to address the persistent sale of unapproved vaping products.

Nov.25 by 2FIRSTS.ai

ceshi1111

Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st